Virax Biolabs Debuts ImmuneSelect Portfolio
Company Announcements

Virax Biolabs Debuts ImmuneSelect Portfolio

Virax Biolabs Group Ltd. Class A (VRAX) has released an update.

Virax Biolabs Group Ltd. has launched ImmuneSelect, a new suite of immune profiling solutions aimed at understanding adaptive immunity and post-viral syndromes like Long COVID. The portfolio, introduced at the ESCMID Global 2024 Congress, includes various tools for research use, such as peptide pools and recombinant antibodies, to assess and monitor T-Cell functions. This marks a significant step towards the eventual commercialization of their ViraxImmune T-Cell diagnostic platform.

For further insights into VRAX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskVirax Biolabs Sets Date for 2024 AGM
TipRanks Auto-Generated NewsdeskVirax Biolabs Expands Reach with Europa Biosite Deal
TheFlyVirax Biolabs announces distribution agreement with Europa Biosite
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App